January 14, 2026
BioDelivery Sciences International needed to pursue a contempt order, not an enforcement action, when alleging a 2022 injunction blocking Alvogen's generic version of its Belbuca opioid film should be applied to a new generic application, a Delaware federal judge held in a case where he was already "frustrated (and exhausted)."
December 20, 2021
A Delaware federal judge on Monday upheld claims in two patents that BioDelivery Sciences International Inc. accused Alvogen PB Research and Development LLC of infringing with a planned generic of the opioid pain medication Belbuca, but invalidated claims in a third.